Notably, numerous pre-clinical studies have found that administration of Flt3L prior to transplant can alleviate GvHD and enhance GvL, while administration of Flt3L after transplant significantly exacerbates GvHD by stimulating donor stem cells to proliferate (24, 28, 68, 69). The gene discussed is FLT3LG; the disease is graft versus host disease.